142 related articles for article (PubMed ID: 35406486)
1. Converged DNA Damage Response Renders Human Hepatocellular Carcinoma Sensitive to CDK7 Inhibition.
Xie G; Zhu A; Gu X
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406486
[TBL] [Abstract][Full Text] [Related]
2. CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer.
Zhong S; Zhang Y; Yin X; Di W
Onco Targets Ther; 2019; 12():2137-2147. PubMed ID: 30962695
[TBL] [Abstract][Full Text] [Related]
3. CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism.
Abudureheman T; Xia J; Li MH; Zhou H; Zheng WW; Zhou N; Shi RY; Zhu JM; Yang LT; Chen L; Zheng L; Xue K; Qing K; Duan CW
Front Oncol; 2021; 11():663360. PubMed ID: 33889549
[TBL] [Abstract][Full Text] [Related]
4. THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer.
Lu P; Geng J; Zhang L; Wang Y; Niu N; Fang Y; Liu F; Shi J; Zhang ZG; Sun YW; Wang LW; Tang Y; Xue J
Oncogene; 2019 May; 38(20):3932-3945. PubMed ID: 30692639
[TBL] [Abstract][Full Text] [Related]
5. CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition.
McDermott MSJ; Sharko AC; Munie J; Kassler S; Melendez T; Lim CU; Broude EV
Cells; 2020 Mar; 9(3):. PubMed ID: 32155786
[TBL] [Abstract][Full Text] [Related]
6. Nanomaterial-Facilitated Cyclin-Dependent Kinase 7 Inhibition Suppresses Gallbladder Cancer Progression via Targeting Transcriptional Addiction.
Huang CS; Xu QC; Dai C; Wang L; Tien YC; Li F; Su Q; Huang XT; Wu J; Zhao W; Yin XY
ACS Nano; 2021 Sep; 15(9):14744-14755. PubMed ID: 34405985
[TBL] [Abstract][Full Text] [Related]
7. Co-overexpression of BRD4 and CDK7 promotes cell proliferation and predicts poor prognosis in HCC.
Li X; Zheng C; Liu Y; Sun H; Qian Y; Fan H
Heliyon; 2024 Jan; 10(2):e24389. PubMed ID: 38293462
[TBL] [Abstract][Full Text] [Related]
8. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Zeng M; Kwiatkowski NP; Zhang T; Nabet B; Xu M; Liang Y; Quan C; Wang J; Hao M; Palakurthi S; Zhou S; Zeng Q; Kirschmeier PT; Meghani K; Leggett AL; Qi J; Shapiro GI; Liu JF; Matulonis UA; Lin CY; Konstantinopoulos PA; Gray NS
Elife; 2018 Nov; 7():. PubMed ID: 30422115
[TBL] [Abstract][Full Text] [Related]
9. THZ1, a covalent CDK7 inhibitor, enhances gemcitabine-induced cytotoxicity via suppression of Bcl-2 in urothelial carcinoma.
Kuo KL; Lin WC; Liu SH; Hsu FS; Kuo Y; Liao SM; Yang SP; Wang ZH; Hsu CH; Huang KH
Am J Cancer Res; 2021; 11(1):171-180. PubMed ID: 33520367
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Targeting of CDK7 Suppresses Tumor Progression in Intrahepatic Cholangiocarcinoma.
Chen HD; Huang CS; Xu QC; Li F; Huang XT; Wang JQ; Li SJ; Zhao W; Yin XY
Int J Biol Sci; 2020; 16(7):1207-1217. PubMed ID: 32174795
[TBL] [Abstract][Full Text] [Related]
11. Effect of CDK7 inhibitor on MYCN-amplified retinoblastoma.
Xu H; Xiao L; Chen Y; Liu Y; Zhang Y; Gao Y; Man S; Yan N; Zhang M
Biochim Biophys Acta Gene Regul Mech; 2023 Sep; 1866(3):194964. PubMed ID: 37536559
[TBL] [Abstract][Full Text] [Related]
12. Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma.
Greenall SA; Lim YC; Mitchell CB; Ensbey KS; Stringer BW; Wilding AL; O'Neill GM; McDonald KL; Gough DJ; Day BW; Johns TG
Oncogenesis; 2017 May; 6(5):e336. PubMed ID: 28504693
[TBL] [Abstract][Full Text] [Related]
13. Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer.
Zhou Y; Lu L; Jiang G; Chen Z; Li J; An P; Chen L; Du J; Wang H
Cell Death Differ; 2019 Aug; 26(8):1442-1452. PubMed ID: 30451989
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Zhou X; Zhu A; Gu X; Xie G
Cell Oncol (Dordr); 2019 Jun; 42(3):369-380. PubMed ID: 30788663
[TBL] [Abstract][Full Text] [Related]
15. SOX9 interacts with FOXC1 to activate MYC and regulate CDK7 inhibitor sensitivity in triple-negative breast cancer.
Tang L; Jin J; Xu K; Wang X; Tang J; Guan X
Oncogenesis; 2020 May; 9(5):47. PubMed ID: 32398735
[TBL] [Abstract][Full Text] [Related]
16. Adenine inhibits growth of hepatocellular carcinoma cells via AMPK-mediated S phase arrest and apoptotic cascade.
Su WW; Huang JY; Chen HM; Lin JT; Kao SH
Int J Med Sci; 2020; 17(5):678-684. PubMed ID: 32210718
[No Abstract] [Full Text] [Related]
17. Aberrant Super-Enhancer Landscape in Human Hepatocellular Carcinoma.
Tsang FH; Law CT; Tang TC; Cheng CL; Chin DW; Tam WV; Wei L; Wong CC; Ng IO; Wong CM
Hepatology; 2019 Jun; 69(6):2502-2517. PubMed ID: 30723918
[TBL] [Abstract][Full Text] [Related]
18. Elevation of effective p53 expression sensitizes wild-type p53 breast cancer cells to CDK7 inhibitor THZ1.
Wang Y; Zhang Z; Mi X; Li M; Huang D; Song T; Qi X; Yang M
Cell Commun Signal; 2022 Sep; 20(1):96. PubMed ID: 36058938
[TBL] [Abstract][Full Text] [Related]
19. Pseudolaric acid B exhibits anti-cancer activity on human hepatocellular carcinoma through inhibition of multiple carcinogenic signaling pathways.
Zhang H; Li JC; Luo H; Zhao L; Zhang ZD; Shen XF
Phytomedicine; 2019 Jun; 59():152759. PubMed ID: 31004883
[TBL] [Abstract][Full Text] [Related]
20. JS-K, a nitric oxide prodrug, induces DNA damage and apoptosis in HBV-positive hepatocellular carcinoma HepG2.2.15 cell.
Liu Z; Li G; Gou Y; Xiao D; Luo G; Saavedra JE; Liu J; Wang H
Biomed Pharmacother; 2017 Aug; 92():989-997. PubMed ID: 28605880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
